



New Drug

Landiolol (Rapiblyk)



Why it matters:

Using rapid-acting IV beta-blockers for some abnormal heart rhythms can help treat patients quicker and allow them to transfer out of intensive care units faster. Landiolol is a continuously infused beta-blocker similar to esmolol, but its clearance half-life (4 minutes) is twice as fast.



What else to know:

It is the only available beta-blocker that comes as a powder vial that requires reconstitution. Similar to other IV beta-blockers, treat it as a high alert medication.

Manufacturer	AOP Orphan Pharmaceuticals
Approved use	Short-term reduction of ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter
Approval date	November 2024
Anticipated availability	Available now
Dosage and administration	<p><u>Normal cardiac function</u>: Start at 9 mcg/kg/min and titrate in 9 mcg/kg/min increments every 10 minutes as needed</p> <p><u>Impaired cardiac function (heart failure, etc)</u>: Start at 1 mcg/kg/min and titrate in 1 mcg/kg/min increments every 15 minutes as needed</p> <p><u>Maximum dose</u>: 36 mcg/kg/min (regardless of cardiac function), and limit treatment duration to no more than 24 hours</p>
Storage requirements	<ul style="list-style-type: none"> • Store unopened vials at room temperature (20 to 25°C) • Beyond-use dates at 25°C depend on the reconstitution diluent: <ul style="list-style-type: none"> ◦ Sodium chloride 0.9%: 4 hours ◦ Dextrose 5%: 48 hours
Prescribing information	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf



New Drug

Landiolol (Rapiblyk)

References:

- Cafaro T, Allwood M, McIntyre WF, et al. Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis. *Can J Anaesth*. 2023 Nov;70(11):1828-1838.
- Levy B, Slama M, Lakbar I, et al. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. *J Clin Med*. 2024 May 17;13(10):2951.
- Fellahi JL, Heringlake M, Knotzer J, et al. Landiolol for managing atrial fibrillation in post-cardiac surgery. *Eur Heart J Suppl*. 2018 Jan;20(Suppl A):A4-A9.
- Product information for landiolol (Rapiblyk). AOP Orphan Pharmaceuticals GmbH. 1190 Vienna, Austria. November 2024.

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

Copyright © 2025 by Therapeutic Research Center. All Rights Reserved. trchealthcare.com